Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Pediatr Endocrinol Metab ; 34(8): 1055-1060, 2021 Aug 26.
Artículo en Inglés | MEDLINE | ID: mdl-33866705

RESUMEN

OBJECTIVES: Nutritional rickets may be a preventable cause of craniosynostosis. This potential association is under-recognised. A late diagnosis of craniosynostosis may result in reduced brain growth, raised intracranial pressure and long-term psychosocial problems. CASE PRESENTATION: We present four cases of craniosynostosis associated with nutritional rickets. Those who had delayed presentation underwent emergency craniotomy. CONCLUSIONS: Treatment of nutritional rickets and early identification of craniosynostosis can reduce morbidity in these children.


Asunto(s)
Craneosinostosis/patología , Raquitismo Hipofosfatémico Familiar/complicaciones , Preescolar , Craneosinostosis/etiología , Femenino , Humanos , Lactante , Masculino , Pronóstico
2.
Acta Paediatr ; 110(6): 1855-1862, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-33145793

RESUMEN

AIM: This study aimed to identify current trends in the management of metabolic bone disease of prematurity (MBDP) in the United Kingdom. METHODS: A nationwide electronic survey was disseminated to all neonatal networks across the United Kingdom, as well as to paediatric endocrinologists for comparison. Weighted averages were used to compare relative importance placed on screening and diagnostic investigations (1 = not important, 5 = essential). RESULTS: Sixty-nine individuals responded from 53 neonatal units. Greatest emphasis was placed on levels of serum phosphate and alkaline phosphatase for screening (weighted average 4.5 and 4.6, respectively), diagnosis (weighted average 4.1 and 4.5, respectively) and monitoring (93% and 97% of neonatal responders, respectively) of MBDP by neonatologists. Although similar results were obtained for endocrinologists, significantly greater emphasis was placed on plasma parathyroid hormone (PTH) level for screening, diagnosis and monitoring (p < 0.001 for each). Phosphate supplementation was reported almost universally by neonatal responders (99%), but was significantly less for endocrine responders (62%) for the treatment of MBDP (p < 0.001). CONCLUSION: There is an under-utilisation of plasma PTH as a screening, diagnostic and monitoring investigation to guide appropriate supplementation for MBDP by neonatologists.


Asunto(s)
Enfermedades Óseas Metabólicas , Enfermedades del Prematuro , Enfermedades Óseas Metabólicas/diagnóstico , Calcio , Niño , Humanos , Recién Nacido de Bajo Peso , Recién Nacido , Hormona Paratiroidea , Reino Unido
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA